SecBot SecBot
SECBOTREPLAY Home › Report › IRON

IRON · Disc Medicine announced alignment with the FDA that the ongoing Phase 3…

Disc Medicine Inc · PRESS-RELEASE filed Jun 9, 2026 at 08:30 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 9, 2026 at 08:30 ET

Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for responding to the CRL for bitopertin in EPP and potentially support traditional approval. This provides a clearer path forward after the CRL, reducing regulatory uncertainty. APOLLO data is expected in Q4 2026, with an FDA decision by mid-2027.

  • FDA aligned that successful Phase 3 APOLLO study can support CRL response and potentially traditional approval.
  • APOLLO data expected in Q4 2026; CRL response submission by end of 2026.
  • FDA decision on bitopertin expected by mid-2027.
  • Bitopertin is a potential first disease-modifying therapy for EPP.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access